Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC).
Robert A. Figlin
Consultant or Advisory Role - Argos Therapeutics (U); AVEO (U); Bristol-Myers Squibb (U); Prometheus (U)
Research Funding - Argos Therapeutics
Asim Amin
Consultant or Advisory Role - Argos Therapeutics (U)
Arkadiusz Dudek
Consultant or Advisory Role - Argos Therapeutics (U)
Theodore Logan
Consultant or Advisory Role - Argos Therapeutics (U)
Raymond S. Lance
No relevant relationships to disclose
Jeffrey M. Holzbeierlein
No relevant relationships to disclose
Viraj A. Master
No relevant relationships to disclose
Sumanta Kumar Pal
Consultant or Advisory Role - Genentech; Novartis
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Sanofi
Alicia H. Gamble
Employment or Leadership Position - Argos Therapeutics
Mark DeBenedette
Employment or Leadership Position - Argos Therapeutics
Irina Y. Tcherepanova
Employment or Leadership Position - Argos Therapeutics
W. Lee Williams
Employment or Leadership Position - Argos Therapeutics
Doug Plessinger
Employment or Leadership Position - Argos Therapeutics
Consultant or Advisory Role - Axcelo MSL Solutions
Stock Ownership - Argos Therapeutics
Fred Miesowicz
Employment or Leadership Position - Argos Therapeutics
Stock Ownership - Argos Therapeutics
Charles A. Nicolette
Employment or Leadership Position - Argos Therapeutics
Stock Ownership - Argos Therapeutics